STRECK PAUL 4

What Happened
Paul Streck, EVP and Head of R&D at PepGen (PEPG), received equity awards on March 1, 2026: 50,300 restricted stock units (RSUs) and a derivative award (an option) covering 196,500 shares. Both grants were reported on a Form 4 with an acquisition price of $0 per share (typical for compensation grants). These are grants—not open-market purchases or sales—and do not represent realized cash value until vesting/exercise.

Key Details

• Transaction date: 2026-03-01; Filing date (Form 4): 2026-03-02 (appears timely).
• Grants reported: 50,300 RSUs (acquired at $0) and a derivative award/option for 196,500 shares (acquired at $0). Total rights: 246,800 shares.
• Vesting (from filing footnotes): RSUs vest in equal annual installments over 4 years, first vesting on March 1, 2027. The option vests 25% after one year, then the remaining 75% in 36 equal monthly installments.
• Shares owned after transaction: not specified in the provided filing excerpt.
• No 10b5-1 plan, tax-withholding sale, or immediate exercise/sale was disclosed in the filing.

Context
These awards are standard executive compensation (RSUs and an option grant). The option grant is a derivative award that becomes exercisable over time per the vesting schedule — it was granted, not exercised. Such grants are routine and indicate compensation alignment with shareholder interests but do not by themselves signal an insider buying or selling.